Quantum BioPharma Ltd. (CSE: QNTM)
Canada
· Delayed Price · Currency is CAD
5.46
+0.21 (4.00%)
Dec 20, 2024, 10:12 AM EST
Quantum BioPharma Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | 2018 - 2016 |
---|---|---|---|---|---|---|---|
Period Ending | Sep '24 Sep 29, 2024 | Dec '23 Dec 30, 2023 | Dec '22 Dec 30, 2022 | Dec '21 Dec 30, 2021 | Dec '20 Dec 30, 2020 | Dec '19 Dec 30, 2019 | 2018 - 2016 |
Selling, General & Admin | 8.85 | 9.03 | 14.45 | 15.93 | 10.06 | 8.41 | Upgrade
|
Research & Development | 1.77 | 3.86 | 6.91 | 6.33 | 7.83 | - | Upgrade
|
Operating Expenses | 11.46 | 19.23 | 27.43 | 33.74 | 29.84 | 22.43 | Upgrade
|
Operating Income | -11.46 | -19.23 | -27.43 | -33.74 | -29.84 | -22.43 | Upgrade
|
Interest Expense | -0.03 | -0 | -0.05 | -0.07 | -0.24 | -0.16 | Upgrade
|
Interest & Investment Income | 0.59 | 0.79 | 0.37 | 0 | 0 | - | Upgrade
|
Other Non Operating Income (Expenses) | 0.13 | 0.21 | 0.52 | 0.68 | 2.56 | -2.64 | Upgrade
|
EBT Excluding Unusual Items | -10.77 | -18.24 | -26.59 | -33.13 | -27.51 | -25.23 | Upgrade
|
Gain (Loss) on Sale of Investments | -0.1 | -0.38 | -0.23 | -0.86 | -0.77 | -8.78 | Upgrade
|
Asset Writedown | -0.24 | -4.56 | - | - | -0.09 | -0.05 | Upgrade
|
Legal Settlements | - | - | - | - | -0.76 | - | Upgrade
|
Other Unusual Items | -0.01 | 4.94 | 0.12 | 0.05 | 0.68 | -0.02 | Upgrade
|
Pretax Income | -11.11 | -18.23 | -26.7 | -33.94 | -28.45 | -34.08 | Upgrade
|
Earnings From Continuing Operations | -11.11 | -18.23 | -26.7 | -33.94 | -28.45 | -34.08 | Upgrade
|
Earnings From Discontinued Operations | - | - | 3.1 | -1.35 | -3.35 | -5.05 | Upgrade
|
Net Income to Company | -11.11 | -18.23 | -23.61 | -35.29 | -31.8 | -39.13 | Upgrade
|
Minority Interest in Earnings | 0.87 | 0.33 | - | - | - | - | Upgrade
|
Net Income | -10.24 | -17.9 | -23.61 | -35.29 | -31.8 | -39.13 | Upgrade
|
Net Income to Common | -10.24 | -17.9 | -23.61 | -35.29 | -31.8 | -39.13 | Upgrade
|
Shares Outstanding (Basic) | 1 | 1 | 1 | 1 | 0 | 0 | Upgrade
|
Shares Outstanding (Diluted) | 1 | 1 | 1 | 1 | 0 | 0 | Upgrade
|
Shares Change (YoY) | 31.09% | 2.21% | 10.84% | 190.15% | 70.68% | 19.49% | Upgrade
|
EPS (Basic) | -12.91 | -29.39 | -39.62 | -65.63 | -171.62 | -360.45 | Upgrade
|
EPS (Diluted) | -12.91 | -29.39 | -39.62 | -65.63 | -171.62 | -360.45 | Upgrade
|
Free Cash Flow | -6.89 | -10.83 | -28.45 | -20.75 | -19.13 | -13.71 | Upgrade
|
Free Cash Flow Per Share | -8.69 | -17.78 | -47.74 | -38.59 | -103.25 | -126.32 | Upgrade
|
EBITDA | -10.96 | -16.73 | -22.9 | -29.7 | -25.94 | -20.49 | Upgrade
|
D&A For EBITDA | 0.5 | 2.51 | 4.53 | 4.05 | 3.9 | 1.94 | Upgrade
|
EBIT | -11.46 | -19.23 | -27.43 | -33.74 | -29.84 | -22.43 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.